Evidence map›Paper›PMID 23951364›Full record

ArticlePloS one2013

The mechanism of antifungal action of a new polyene macrolide antibiotic antifungalmycin 702 from Streptomyces padanus JAU4234 on the rice sheath blight pathogen Rhizoctonia solani.

Zhi-Qiang Xiong, Xiao-Rong Tu, Sai-Jin Wei, Lin Huang, Xun-Hang Li, Hui Lu, Guo-Quan Tu

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Polyenic Antibiotics and Other Antifungal Compounds Produced by HemolyticInternational journal of molecular sciences · 2022
    Review
  5. Article
  6. Article
  7. Field Sanitation and Foliar Application ofThe plant pathology journal · 2021
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zhi-Qiang XiongKey Laboratory of Synthetic Biology, Institute of Plant Physiology and Ecology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China. zhqxiong@sibs.ac.cn
Xiao-Rong Tu
Sai-Jin Wei
Lin Huang
Xun-Hang Li
Hui Lu
Guo-Quan Tu
Jiangxi Agricultural University · CNCenter for Excellence in Molecular Plant Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antifungalmycin 702, a new polyene macrolide antibiotic produced by Streptomycespadanus JAU4234, has a broad antifungal activity and may have potential future agricultural and/or clinical applications. However, the mechanism of antifungal action of antifungalmycin 702 remains unknown. Antifungalmycin 702 strongly inhibited mycelial growth and sclerotia formation/germination of Rhizoctonia solani. When treated with antifungalmycin 702, the hyphae morphology of R. solani became more irregular. The membrane and the cellular organelles were disrupted and there were many vacuoles in the cellular space. The lesion in the plasma membrane was detected through the increase of membrane permeability, lipid peroxidation and leakage of cell constituents. In summary, antifungalmycin 702 may exert its antifungal activity against R. solani by changing the structure of cell membranes and the cytoskeleton and interacting with the organelles.

Indexed as

Anti-Bacterial AgentsAntifungal AgentsCell MembraneDose-Response Relationship, DrugHyphaeMacrolidesMicrobial Sensitivity TestsOryzaPermeabilityPlant DiseasesPolyenesRhizoctoniaStreptomycesAnti-Bacterial AgentsAntifungal AgentsMacrolidesPolyenes

Identifiers

PMID23951364
PMCPMC3741153
OpenAlexW1977352996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.